Spero

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Retrieved on: 
Wednesday, October 4, 2023
Cream, Taste, Mozzarella sticks, CPG, Cheese, HEALTH, Coolhaus, Milk, Climate change, Acquisition, Engineering, Dairy, Spero

Spero’s mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere.

Key Points: 
  • Spero’s mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere.
  • The acquisition expands Superlatus growing portfolio of CPG brands under their Urgent Company umbrella, joining Coolhaus, Modern Kitchen, Brave Robot, and others.
  • The purchase of Spero will produce affordable, clean, sustainable plant-based dairy and egg alternatives.
  • “We are thrilled to welcome the Spero Food brands to our portfolio of CPG assets,” said Superlatus CEO Timothy Alford.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 29, 2023
Employment, RSU, MDR, Infection, Rare, Therapy, Compensated emancipation, Pharmaceutical industry, Spero

The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).

Key Points: 
  • The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals, entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The RSUs will vest in four equal annual installments beginning on October 2, 2024, subject to the employee's continued employment with Spero on such vesting dates.
  • The RSUs are subject to the terms and conditions of the 2019 Inducement Plan and an RSU agreement covering the grant.

Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference

Retrieved on: 
Wednesday, September 20, 2023
Webcast, Infection, MDR, Rare, Cantor, Spero, Therapy, Conference, Pharmaceutical industry, Online shopping

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald’s Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald’s Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY.
  • Details are as follows:
    The webcast may also be accessed through Spero Therapeutics’ website ( www.sperotherapeutics.com ) on the “Events and Presentations” page under the “Connect” tab.
  • Replays will be available on the website following the conclusion of each event.

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 6, 2023
Webcast, Lotte New York Palace Hotel, Infection, MDR, Rare, Spero, Therapy, Conference, Pharmaceutical industry, Online shopping

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023, at the Lotte New York Palace Hotel in New York, NY.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023, at the Lotte New York Palace Hotel in New York, NY.
  • Details are as follows:
    The webcast may also be accessed through Spero Therapeutics’ website ( www.sperotherapeutics.com ) on the “Events and Presentations” page under the “Connect” tab.
  • Replays will be available on the website following the conclusion of each event.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 31, 2023
Employment, RSU, MDR, Infection, Rare, Therapy, Compensated emancipation, Pharmaceutical industry, Spero

The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).

Key Points: 
  • The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals, entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The RSUs will vest in four equal annual installments beginning on September 1, 2024, subject to the employee's continued employment with Spero on such vesting dates.
  • The RSUs are subject to the terms and conditions of the 2019 Inducement Plan and an RSU agreement covering the grant.

Confirm Raises $6.2 Million in Series A Funding to Remove Politics and Subjectivity From Performance Reviews

Retrieved on: 
Wednesday, August 30, 2023
Software, Networks, Human Resources, Artificial Intelligence, Data Management, Professional Services, Technology, Business, Great Resignation, Confirmation, PIP, Marketing, Workplace, ONA, SHRM, General partnership, Talent management, The People's Operator, Science, Organization, Spero, Traction, Organizational network analysis, HR, Growth, Bias, Lighthouse, Cryptocurrency, Risk management

The round was led by Spero Ventures with participation from SHRMLabs, Elefund, Gaingels, Black Angel Group and several existing customers.

Key Points: 
  • The round was led by Spero Ventures with participation from SHRMLabs, Elefund, Gaingels, Black Angel Group and several existing customers.
  • “Performance reviews are broken –– and approaches like continuous feedback and 360 assessments that claim to be the solution are actually making them worse,” said Josh Merrill, co-founder and CEO of Confirm.
  • Confirm will use the new funds to fuel product development and boost investment in sales and marketing.
  • “Organizational Network Analysis (ONA) is an absolute breakthrough with performance management; it is exceptionally insightful.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Retrieved on: 
Thursday, August 3, 2023
Infection, MDR, Rare, Spero, Therapy, Pharmaceutical industry, Online shopping

ET to report its second quarter 2023 financial results and provide an update on its business and pipeline.

Key Points: 
  • ET to report its second quarter 2023 financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10022241, or click on this link and request a return call.
  • The audio webcast can be accessed on the "Events and Presentations" page under the “Connect” tab of the Company's website at www.sperotherapeutics.com .
  • The archived webcast will also be available on Spero's website for 30 days following the call.

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Retrieved on: 
Monday, July 31, 2023
GSK, IV, Prevalence, HBR, Pyelonephritis, Cutis verticis gyrata, AP, MDR, Patient, SPA, Infection, Rare, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Spero

CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in areas of high unmet need involving rare diseases and multi-drug resistant (MDR) bacterial infections, announced today that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design and size of PIVOT-PO, a pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP).

Key Points: 
  • “PIVOT-PO was designed in collaboration with GSK to provide tebipenem HBr with a clinical path to becoming the first oral carbapenem antibiotic for treatment of cUTI, if approved,” said Dr. Kamal Hamed, Chief Medical Officer of Spero.
  • “With increasing prevalence of antibiotic-resistant bacteria, cUTI patients often have no choice but to receive an intravenous (IV) carbapenem antibiotic in a hospital setting.
  • The goal of our tebipenem HBr program is to provide appropriate patients with an efficacious oral option for the treatment of cUTI.
  • We believe that tebipenem HBr has the potential to deliver strong value to the healthcare system.”
    PIVOT-PO is a global, randomized, double-blind, pivotal Phase 3 clinical trial of oral tebipenem HBr vs. IV imipenem cilastatin, in hospitalized adult patients with cUTI/AP.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, June 30, 2023
Infection, MDR, Employment, Rare, Therapy, RSU, Compensated emancipation, Pharmaceutical industry, Spero

The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The RSUs will vest in four equal annual installments beginning on July 3, 2024, subject to the employee's continued employment with Spero on such vesting dates.
  • The RSUs are subject to the terms and conditions of the 2019 Inducement Plan and an RSU agreement covering the grant.

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Retrieved on: 
Wednesday, June 14, 2023
GSK, Interim, HBR, Penn State Board of Trustees, Culture, Infection, PFE, Pfizer, Shukla, Accounting, MDR, M.D, Spero, Interim management, MD, Patient, Rare, Treasurer, Therapy, NYSE, Management, Pharmaceutical industry, Vertex, Ankit

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat “Sath” Shukla, Spero’s current Chief Financial Officer and Treasurer, will serve as Spero’s President and Chief Executive Officer (CEO), and as a member of the Board of Directors, effective August 1, 2023.

Key Points: 
  • Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023
    Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors
    CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat “Sath” Shukla, Spero’s current Chief Financial Officer and Treasurer, will serve as Spero’s President and Chief Executive Officer (CEO), and as a member of the Board of Directors, effective August 1, 2023.
  • Mr. Shukla will succeed Spero’s current CEO and President, Ankit Mahadevia, M.D., who will become Chairman of the Board of Directors, effective August 1, 2023.
  • “It has been an honor to lead Spero since its inception and I am thrilled to welcome Sath as our next CEO,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
  • Until this search is completed, the Board has appointed Stephen J. DiPalma as Interim CFO and Treasurer, effective August 1, 2023.